Statera Biopharma, Inc. Common Stock
STAB
STAB was delisted on the 11th of January, 2023.
18 hedge funds and large institutions have $1.77M invested in Statera Biopharma, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 3 closing their positions.
17% more capital invested
Capital invested by funds: $1.51M → $1.77M (+$257K)
5% less funds holding
Funds holding: 19 → 18 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$73K |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$31.7K |
| 3 |
BlackRock
New York
|
+$1.34K |
| 4 |
SWP
Stratos Wealth Partners
Beachwood,
Ohio
|
+$304 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$39K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$35K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$11.6K |
| 4 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$10.8K |
| 5 |
TDC
Thompson Davis & Co
Richmond,
Virginia
|
-$5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $966K | +$73K | +24,000 | +11% |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $631K | -$39K | -12,842 | -8% |
|
3
Geode Capital Management
Boston,
Massachusetts
| $66K | – | – | – |
|
|
4
BlackRock
New York
| $59K | +$1.34K | +440 | +3% |
|
|
PAM
5
Panagora Asset Management
Boston,
Massachusetts
| $42K | +$31.7K | +10,427 | New |
|
|
WA
6
Winfield Associates
Cleveland,
Ohio
| $3K | – | – | – |
|
|
IA
7
IFP Advisors
Tampa,
Florida
| $1K | -$1.52K | -500 | -77% |
|
|
8
Citadel Advisors
Miami,
Florida
| – | -$35K | -10,032 | Closed |
|
|
9
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$11.6K | -3,800 | -100% |
|
|
LTFS
10
Ladenburg Thalmann Financial Services
Miami,
Florida
| – | -$10.8K | -3,550 | -99% |
|
|
TDC
11
Thompson Davis & Co
Richmond,
Virginia
| – | -$5K | -1,334 | Closed |
|
12
UBS Group
Zurich,
Switzerland
| – | -$1K | -364 | Closed |
|
13
Wells Fargo
San Francisco,
California
| – | -$912 | -300 | -67% |
|
|
AG
14
Advisor Group
Phoenix,
Arizona
| – | -$36 | -12 | -32% |
|
|
SWP
15
Stratos Wealth Partners
Beachwood,
Ohio
| – | +$304 | +100 | New |
|
STAB Hedge Fund Activity: Q4 2017 in Review
18 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q4 2017, worth a combined $1.77M — up 17% from $1.51M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of STAB and 2 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 2 added.
The largest buyer was Renaissance Technologies, adding an estimated $73K. The largest seller was Vanguard Group, cutting an estimated $39K.
- 18 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q4 2017, down from 19 in Q3 2017.
- Funds reported $1.77M of Statera Biopharma, Inc. Common Stock stock for Q4 2017, up 17% quarter-over-quarter.
- 2 funds opened new Statera Biopharma, Inc. Common Stock positions in Q4 2017 and 3 closed out, a net change of -1 holder.
- The largest Statera Biopharma, Inc. Common Stock buyer in Q4 2017 was Renaissance Technologies, an estimated $73K added.
- The largest Statera Biopharma, Inc. Common Stock seller in Q4 2017 was Vanguard Group, an estimated $39K sold.
Based on aggregated 13F filings for Q4 2017.